INCY News and Press, Incyte Corporation From 03/18/22

New data on ruxolitinib cream (Opzelura™) in vitiligo and atopic dermatitis will be presented, including 52-week results from the Phase 3 TRuE-V vitiligo program which will be featured as a late-breaking oral presentation Incyte (Nasdaq:INCY) today announced that ...

The U.S. Food and Drug Administration extended the review period by three months for Incyte's (NASDAQ:INCY) application seeking extended approval of ruxolitinib cream (Opzelura) to treat vitiligo. The FDA is now expected to make a decision by July 18, instead of April 18. The extension will a...

Incyte Corporation (Nasdaq:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib cream (Opzelura™) for the treatment of vitiligo. The Prescription Drug User Fee Ac...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q4-2021 13F filings the consensus holdings were updated, 7 stocks were removed and 7 added from the unive...

FHLC is a well-diversified healthcare ETF concentrated on large caps. FHLC generated strong return, and closely replicated returns of S&P 500. FHLC has strong price multiples and financial growth, at par with peers. For further details see: FHLC: Well Diversified, St...

CHICAGO and FORT WORTH, Texas, March 01, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient on a Phase 2 study of elraglusib (9-ING-41) plus retifanlimab combined with gemcitabine/nab-paclitaxel for th...

We are initiating with CTI BioPharma with a buy rating with a TP of USD 7.6 if pacritinib is approved. We opine that CTI BioPharma's current set-up represents an attractive risk-reward scenario with ~50% potential downside (around cash value of $1/share) and ~320% potential upside (bu...

PBE is neither suitable for income seekers, nor for long term investors. Despite being a Genomic revolution fund, it lacks focus, and invested heavily on large cap diverse biotechnology companies. Better biotechnology ETFs of similar nature are available in the market. For f...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips With so much information proliferating the internet about equity market opportunities, it’s hard to know whom to trust. That’s especially the case when you consider insider stocks or transactions that corporat...

Incyte (INCY -2.2%) has extended its post-market losses on Wednesday despite recording better than expected revenue for Q4 2021. Its blockbuster JAK inhibitor, JAKAFI/JAKAVI (ruxolitinib), brought $592M in net product revenue during the quarter with ~15% YoY growth expanding the yearly net pr...